Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Elixinol Wellness ( (AU:EXL) ) has shared an announcement.
Elixinol Wellness Limited has announced the appointment of Gavin Evans as a director, effective December 2, 2025. Evans holds 50,000,000 unlisted options and 7,407,407 fully paid ordinary shares, indicating a significant stake in the company. This appointment may influence the company’s strategic direction and could impact its market positioning, potentially affecting stakeholders’ interests.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
More about Elixinol Wellness
Elixinol Wellness Limited operates in the wellness industry, focusing on the production and distribution of health and wellness products. The company is known for its offerings in the hemp-derived CBD market, catering to consumers seeking natural health solutions.
YTD Price Performance: -71.05%
Average Trading Volume: 554,520
Technical Sentiment Signal: Sell
Current Market Cap: A$4.55M
Find detailed analytics on EXL stock on TipRanks’ Stock Analysis page.